[Pharmacological studies of a new highly effective blood sugar decreasing sulfonamide, glibenclamide (HB 419)].
D000818:Animals; D001786:Blood Glucose / Q000032:analysis*; D003864:Depression, Chemical; D003981:Diazoxide / Q000037:antagonists & inhibitors; D004285:Dogs; D004357:Drug Synergism; D005260:Female; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000494:pharmacology*; D007275:Injections, Intravenous; D007328:Insulin / Q000096:biosynthesis / Q000097:blood / Q000378:metabolism; D000078790:Insulin Secretion; D007515:Islets of Langerhans / Q000187:drug effects / Q000254:growth & development; D008297:Male; D051379:Mice; D010179:Pancreas / Q000187:drug effects / Q000378:metabolism; D010180:Pancreatectomy; D051381:Rats; D013268:Stimulation, Chemical; D014044:Tolbutamide / Q000494:pharmacology; D014508:Urea / Q000008:administration & dosage / Q000494:pharmacology*
D001786:Blood Glucose; D007004:Hypoglycemic Agents; D007328:Insulin; D014508:Urea; D014044:Tolbutamide; D003981:Diazoxide
Pharmakologische Untersuchungen eines neuen hochwirksamen blutzuckersenkenden Sulfonamids, des Glibenclamid (HB 419)